| Literature DB >> 29318549 |
Manu Gnanamony1, Christopher S Gondi2,3,4.
Abstract
Cathepsin B belongs to a family of cathepsins and plays an important role in normal physiological functions in the cell. However, overexpression of cathepsin B has been associated with different malignancies, and this has made it an attractive pharmacological target. The advent of CRISPR-Cas9 technology has allowed researchers to efficiently knock down genes with very less nonspecific activity compared to earlier methods. The protocol described below will enable investigators to develop cathepsin B knockdown stable cells and explains ways to study the knockdown.Entities:
Keywords: Antibody; Cancer target; Cancer therapy; Cathepsin B; Cathepsin B signaling; Inhibitor; RNAi
Mesh:
Substances:
Year: 2018 PMID: 29318549 DOI: 10.1007/978-1-4939-7595-2_12
Source DB: PubMed Journal: Methods Mol Biol ISSN: 1064-3745